Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995358 | 0.87 | BRD4 (0.52) | LMNABRD4ALDH1A1MAPTMPO | |
| SCHEMBL8018423 | 0.86 | ALDH1A1 (0.47) | LMNAALDH1A1MAPTMPOPTGS2 | |
| SCHEMBL13890243 | 0.85 | PTGS2 (0.49) | BRD4PTGS2 | |
| SCHEMBL3724877 | 0.85 | LMNA (0.46) | LMNAALDH1A1MAPTMPOPTGS2 | |
| SCHEMBL1939686 | 0.85 | LMNA (0.50) | LMNAALDH1A1MAPTMPOPTGS2 | |
| SCHEMBL399056 | 0.85 | LMNA (0.46) | LMNAALDH1A1MAPTMPOPTGS2 | |
| SCHEMBL7946185 | 0.84 | VCAM1 (0.38) | LMNAALDH1A1MAPT | |
| SCHEMBL7948250 | 0.84 | GAA (0.44) | ALDH1A1MAPTPTGDR2 | |
| SCHEMBL13995371 | 0.84 | BRD4 (0.44) | LMNABRD4ALDH1A1MAPTMPO | |
| Hydrochloric Acid SCHEMBL1164961 | 0.83 | LMNA (0.45) | LMNAALDH1A1MAPTMPOPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-6258984-B1 | CHLORINATION OF P-ALKYLBENZENESULFONYL CHLORIDE | CLARIANT GMBH (DE) | 2001-07-10 | — | — | US | disclosed |
| EP-0619303-B1 | 4-alkyl-3-chloro-benzenesulfinic acids, 4-alkyl-3-chloro-benzenesulfonic acids, 4-alkyl-3-chloro-alkylsulfonylbenzenes and process for their preparation | HOECHST AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0571405-B1 | Process for preparing 4-alkylsulfonyl-1-alkyl-2-chlorobenzenes and intermediates | HOECHST AG (DE) | 1996-05-01 | — | — | EP | disclosed |
| US-5498798-A | 4-alkyl-3-chlorobenzenesulfinic acids, 4-alkyl-3-chlorobenzenesulfonylcarboxylic acids, 4-alkyl-3-chloroalkylsulfonylbenzenes and preparation thereof | HOECHST AG (DE) | 1996-03-12 | — | — | US | disclosed |
| EP-0619303-A1 | 4-alkyl-3-chloro-benzenesulfinic acids, 4-alkyl-3-chloro-benzenesulfonic acids, 4-alkyl-3-chloro-alkylsulfonylbenzenes and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-12 | — | — | EP | disclosed |
| EP-0571405-A1 | PROCESS FOR PREPARING 4-ALKYLSULFONYL-1-ALKYL-2-CHLOROBENZENES AND THE LIKE. | HOECHST AG (DE) | 1993-12-01 | — | — | EP | disclosed |
| WO-1992014700-A1 | PROCESS FOR PREPARING 4-ALKYLSULFONYL-1-ALKYL-2-CHLOROBENZENES AND THE LIKE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | LMNA 3189/4885BRD4 703/4885ALDH1A1 3140/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | LMNA 3623/4885BRD4 1406/4885ALDH1A1 1364/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | LMNA 101/4885BRD4 53/4885ALDH1A1 1306/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | LMNA 761/4885BRD4 106/4885ALDH1A1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.